CanSense is a med-tech startup focussed on developing a blood-based assay for the non-invasive diagnosis of bowel cancer, using AI-driven models. Colorectal cancer, also referred to as bowel cancer, ranks as the third most common cancer globally. It accounts for approximately 10% of all cancer diagnoses and is the second leading cause of cancer-related deaths worldwide.
“Patients understand the CanSense blood test: it's simple, acceptable and strongly preferred over unnecessary colonoscopies. The ability of the test to detect the earliest signs of cancer is incredibly exciting. What CanSense is doing is really changing the landscape of how we detect cancer for good. It’s a really exciting place to be at the moment.” Professor Dean Harris, Clinical Directory of CanSense.
Cancer can prevent people from living healthier and longer lives, and increase pressures on the health and social care system. We can help improve this by driving life science innovation to the frontline of care.
"Cancer care in Wales is advancing, but challenges remain. By showcasing innovations like QuicDNA and CanSense, we aim to inspire and show how innovative technologies can transform cancer detection and treatment. Partnerships across health, social care, and industry are vital. We foster collaboration to accelerate the deployment of innovative cancer care solutions.” - Cari-Anne Quinn, CEO, Life Sciences Hub Wales
